secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001104659-23-033314
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene option for DKN-01 expired; Leap retains global rights, continues clinical collaboration
--------------------------------------------------------------------------------

- BeiGene's option to license DKN-01 in Asian territories expired; Leap retains global rights.
- Collaboration continues on Part C of DisTinGuish trial (DKN-01 + tislelizumab + chemo) in first-line gastric cancer; enrollment completion expected late 2023.
- Cash runway extended into mid-2025 following Flame Biosciences acquisition; company seeking new strategic partner for DKN-01.
- Company will also develop Claudin18.2 programs acquired from Flame as part of focus on GI cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923033314/0001104659-23-033314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923033314/tm239782d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-033314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer